Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Tevogen advances CRO evaluation to drive $20M+ revenue growth, expand global clinical capabilities, and support a scalable, cash-flow-oriented model.
-
Tevogen regains compliance with Nasdaq minimum bid price requirement.
-
Tevogen.AI head Mittul Mehta to speak at FabCon 2026 on agentic AI and adaptive data pipelines, advancing enterprise-ready intelligent data systems.
-
Tevogen highlights capital discipline, minimal share use, strong insider ownership, and potential acquisitions while exploring ways to reflect asset value
-
WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced performance advancements for its artificial intelligence platform,...
-
Tevogen advances TVGN 489 for Long COVID, expanding HLA coverage to 65% of U.S. population and integrating digital monitoring capabilities.
-
Tevogen names interim leaders to advance diversified growth strategy and evaluate subsidiaries targeting $50M+ in annual revenue.
-
Tevogen CEO outlines potential subsidiary acquisitions targeting $50M+ revenue and positive cash flow to support long-term growth.
-
Tevogen signs LOI to evaluate Apozeal acquisition, advancing U.S.-focused generics strategy with 10 FDA-approved ANDAs and pipeline assets.
-
WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its Board of Directors (the “Board”) has approved a reverse...